# EDGAR Filing Document

**Accession Number:** 0001919246
**File Stem:** 0001753926-25-001425
**Filing Date:** 2025-9
**Character Count:** 31187
**Document Hash:** f58914c7e3261e46e72392e7064a17c1
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001753926-25-001425.hdr.sgml**: 20250903

**ACCESSION NUMBER**: 0001753926-25-001425

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 36

**CONFORMED PERIOD OF REPORT**: 20250902

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20250903

**DATE AS OF CHANGE**: 20250903

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Pelthos Therapeutics Inc.
- **CENTRAL INDEX KEY:** 0001919246
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 863335449
- **STATE OF INCORPORATION:** NV
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41964
- **FILM NUMBER:** 251287822

**BUSINESS ADDRESS:**
- **STREET 1:** 4020 STIRRUP CREEK DRIVE
- **STREET 2:** SUITE 110
- **CITY:** DURHAM
- **STATE:** NC
- **ZIP:** 27703
- **BUSINESS PHONE:** 919-908-2422

**MAIL ADDRESS:**
- **STREET 1:** 4020 STIRRUP CREEK DRIVE
- **STREET 2:** SUITE 110
- **CITY:** DURHAM
- **STATE:** NC
- **ZIP:** 27703

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Channel Therapeutics Corp
- **DATE OF NAME CHANGE:** 20241118

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Chromocell Therapeutics Corp
- **DATE OF NAME CHANGE:** 20220323

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **September 2, 2025**

**Pelthos Therapeutics Inc.**

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Nevada** | **001-41964** | **86-3335449** |
| (State or other jurisdiction<br> of incorporation) | (Commission File Number) | (IRS Employer<br> Identification No.) |

---

---

| | |
|:---|:---|
| **4020 Stirrup Creek Drive, Suite 110**<br> **Durham, NC** | **27703** |
| (Address of registrant's principal executive office) | (Zip code) |

---

Registrant's telephone number, including area code: **(919) 908-2400**

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| Common Stock, par value $0.0001 per share | PTHS | The NYSE American LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 7.01. Regulation FD Disclosure.**

On September 2, 2025, Pelthos Therapeutics Inc. (the "Company") issued a press release announcing that its Chief Executive Officer, Scott Plesha, and Chief Financial Officer, Francis Knuettel II, will present at the Wells Fargo 2025 Healthcare Conference in Boston, Massachusetts. Management's presentation will take place on Wednesday, September 3, 2025 at 1:30 p.m. Eastern Time. A webcast of the presentation will be available on the Events and Presentations pages of the Company's website at https://pelthos.com. Archived replays will be available for 90 days following the conference. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

At the conference, the Company will provide an update on its product pipeline and discuss recent business developments, including its commercial launch of ZELSUVMI<sup>TM</sup>. The presentation materials furnished herewith as Exhibit 99.2 (the "Presentation Materials") will be used in connection with such presentation, are incorporated into this Item 7.01 by reference and will be posted on the Company's website at https://pelthos.com. Information contained on the Company's website is not incorporated by reference into and should not be considered to be part of this Current Report on Form 8-K.

The information contained in this Item 7.01, including Exhibits 99.1 and 99.2 attached hereto, which are incorporated into this Item 7.01 by reference, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the "Securities Act"), or the Exchange Act, except as expressly set forth by specific reference in such filing. The information set forth in this Item 7.01 and Exhibits 99.1 and 99.2 attached hereto shall not be deemed an admission as to the materiality of any information in this Current Report on Form 8-K that is required to be disclosed solely to satisfy the requirements of Regulation FD.

**Forward-Looking Statements**

Exhibit 99.2 attached hereto contains forward-looking statements, as defined in Section 21E of the Securities Exchange Act of 1934, regarding the Company's current expectations. All statements, other than statements of historical fact, could be deemed to be forward-looking statements. In some instances, words such as "plans," "believes," "expects," "anticipates," and "will," and similar expressions, are intended to identify forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect our good faith beliefs (or those of the indicated third parties) and speak only as of the date hereof. These forward-looking statements include, without limitation, references to our expectations regarding (i) the success of the launch for ZELSUVMI, (ii) the Company's ability to develop its pipeline, (iii) the Company's ability to protect its intellectual property and to enforce its intellectual property rights, and (iv) the Company's ability to execute its development strategy and sustain its competitive position. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Factors that could cause actual results to differ materially from those set forth in such forward-looking statements include, but are not limited to, risks and uncertainties related to there being no guarantee that the trading price of the combined company's Common Stock will be indicative of the combined company's value or that the combined company's Common Stock will become an attractive investment in the future; we may rely on collaborative partners for milestone payments, royalties, materials revenue, contract payments and other revenue projections and may not receive expected revenue; we and our partners may not be able to timely or successfully advance any product(s) in our internal or partnered pipeline or receive regulatory approval and there may not be a market for the product(s) even if successfully developed and approved; and changes in general economic conditions, including as a result of war, conflict, epidemic diseases, the implementation of tariffs, and ongoing or future litigation could expose us to significant liabilities and have a material adverse effect on us. These and other risks and uncertainties are described more fully in our filings with the U.S. Securities and Exchange Commission. The information in this Current Report on Form 8-K is provided only as of the date of this Current Report on Form 8-K, and we undertake no obligation to update any forward-looking statements contained in this Current Report on Form 8-K based on new information, future events, or otherwise, except as required by law.

**Item 9.01. Financial Statements and Exhibits**

**(d)** **Exhibits:** 

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| [99.1](g084940_ex99-1.htm) | [Press Release, dated September 2, 2025.](g084940_ex99-1.htm) |
| [99.2](g084940_ex99-2.htm) | [Pelthos Therapeutics Inc. Q3 2025 Presentation](g084940_ex99-2.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
| Date: September 3, 2025 | **Pelthos Therapeutics Inc.** | **Pelthos Therapeutics Inc.** | **Pelthos Therapeutics Inc.** |
|  | By: | /s/ Francis Knuettel II | /s/ Francis Knuettel II |
|  |  | Name: | Francis Knuettel II |
|  |  | Title: | Chief Financial Officer |

---

## Exhibit 99.1

**Exhibit 99.1**

![](img002_v1.jpg)

Q 3 2 0 2 5 1

![](img003_v1.jpg)

**Legal Disclaimer** This presentation of Pelthos Therapeutics Inc. ("we", "us", "our" or the "Company") contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict, "project," "seek," "should," "target," "will," "would" or similar expressions and the negatives of those term are intended to identify forward-looking statements. Forward-looking statements reflect management's current expectations, are based on judgments and assumptions, are inherently uncertain and are subject to risks, uncertainties and other factors, which could cause the Company's actual results, performance or achievements to differ materially from expected future results, performance or achievements expressed or implied in those forward-looking statements. Examples of these forward-looking statements and the related risks, uncertainties and other factors include, but are not limited to, the following: the success of the launch for Zesluvmi, timing, progress and results of any preclinical and clinical trials, its estimates regarding the potential market opportunity for Zelsuvmi, its ability to develop its pipeline, its ability to protect its intellectual property and enforce its intellectual property rights, and its ability to execute its development strategy and sustain its competitive position. Actual future results and trends may differ materially depending on a variety of factors, including, but not limited to, the Company's limited operating history, the Company's ability to establish its market development capabilities to commercialize its products and generate any revenue, and the Company's ability to maintain regulatory approval of Zelsuvmi. Forward-looking statements are provided to allow potential investors the opportunity to understan management's beliefs and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment. These statements are not guarantees of future performance and undue reliance should not be placed on them. Any forward-looking statement in this presentation, in any related presentation supplement and in any related free writing presentation reflects our current view with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our business, results of operations, industry and future growth. You should read this presentation with the understanding that our actual future results may be materially different from any future results expressed or implied by these forward-looking statements. Except as required by law, we assume no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future. 2

![](img004_v1.jpg)

 **Corporate Profile Pelthos Therapeutics is a bio-pharmaceutical company committed to commercializing innovative, safe, and efficacious therapeutic products to help patients with unmet treatment burdens <u>Commercial launch</u>** of first drug Zelsuvmi, for the treatment of *Molluscum contagiosum* ("MC") in July 2025 First and only at home treatment for a large, underserved market treating contagious viral disease 16.7 million affected people Up to 6 million annual cases in the U.S. Total addressable market worth in excess of $20 billion at our WAC Experienced management team with over 20 successful prior drug launches and continued growth, including Cosentyx, Otezla, Ohtuvayre, Xifaxan Upside option on NaV pain programs from predecessor Current peak Net Revenue forecast of $175M per annum by 2028 and currently meeting or exceeding internal milestones **Key Data Points (as of 08/29/25, except where noted) Ticker** PTHS **Stock Price** $23.65 **O/S Shares of** 8.8M **Common Stock (on an as converted basis)\* Market CAP** ~$205M **Avg. Daily 59000 shares** 12,300 shares **Trading Volume Cash at close of** $27.5M **merger Investment to** >$400M **date** 3

![](img005_v1.jpg)

 **Management Team** Scott Plesha \| **Chief Executive Officer** • >30 years of experience in the pharmaceutical industry, including two decades building and leading specialty pharma commercial efforts • President and Chief Commercial Officer at BDSI until it was acquired by Collegium Pharmaceutical in 2022 • Grew BDSI sales from $5 million to $160 million • Previously served as Senior Vice President of Gastrointestinal Sales at Salix Pharmaceuticals. During fifteen-year tenure at Salix, led nationwide salesforce that grew product sales to more than $1.5 billion annually • Earned a BA in Pre-Medicine and Pre-Medical Studies at DePauw University and pursued graduate studies in Dentistry at Indiana University Dental School Frank Knuettel \| **Chief Financial Officer** • 30 years of management experience in growing early-stage companies • Raised more than $400 million via venture, public equity and debt offerings and managed more than 15 mergers and acquisition transactions along with large-scale licensing transactions with fortune 50 companies • Holds numerous board positions, at both public and private companies, including Etheros Pharmaceuticals • Earned an MBA from The Wharton School and a BA from Tufts University Sai Rangarao \| **Chief Commercial Officer** • >18 years of experience leading, launching, and marketing pharmaceutical products • VP of Marketing & Head of Neurology Sales at Collegium Pharmaceutical • VP of Marketing & Commercial Operations at BDSI, until it was acquired by Collegium in 2022 • Head of US Dermatology Marketing for Otezla at Celgene leading to acquisition by Amgen for $13 Billion • Member of the commercial and marketing organization at Novartis Pharmaceuticals that launched COSENTYX<sup>®</sup> in the U.S • Earned an MS in Bioscience Regulatory Affairs from The Johns Hopkins University, an MBA and MS from the New Jersey Institute of Technology, and a BS in Computer Science from Indiana University of Pennsylvania 4

![](img006_v1.jpg)

 **Board of Directors Peter Greenleaf, Chairman <sup>Richard Baxter</sup> Todd Davis Ezra Friedberg Richard Malamut , MD <sup>Matt Pauls</sup> Scott Plesha** 5

![](img007_v1.jpg)

 **Molluscum & Zelsuvmi Overview**

![](img008_v1.jpg)

7 **Molluscum Contagiosum** A highly infectious viral condition primarily affecting children 1 year of age or older There are **four known types** of MC virus (MCV1, 2, 3, 4) with MCV1 being the most common1 **Molluscum Contagiosum** is caused by a pox virus and is characterized by small, round, firm, umbilicated, often painless bumps. Even after healing, re-infection is possible if in contact with an infected person or object4. ~17 million people infected in the U.S. MC can take up to **five years to resolve** without treatment2 Peak incidence between 1-10 years of age. Up to **73% of children go untreated**3 **Point prevalence of 3-6 million children** (ages 0-16) in the U.S. **Infection, Persistence, and Spread Visible and Psychological Impacts Pain & Skin Irritation Auto- inoculation2 Highly contagious to others ↑ risk of secondary bacterial infections2 Potential worsening of atopic dermatitis Itching, redness Inflammation Anxiety Social withdrawal Untreated Molluscum Contagiosum Has Severe Effects** 1) Hebert AA, Bhatia N, Del Rosso JQ. Molluscum Contagiosum: Epidemiology, Considerations, Treatment Options, and Therapeutic Gaps. J Clin Aesthet Dermatol. 2023 Aug;16(8 Suppl 2):S4-S11. PMID: 37636018; PMCID: PMC10453394. 2.)Ludmann P. American Academy of Dermatology. Molluscum contagiosum. 4 October 2023. 3) Basdag H, Rainer BM, Cohen BA. Molluscum contagiosum: to treat or not to treat? Experience with 170 children in an outpatient clinic setting in the northeastern United States. Pediatr Dermatol. 2015;32(3):353-357. doi:10.1111/pde.12504. 4) Schaffer JV, Berger EM. Molluscum Contagiosum. JAMA Dermatol. 2016;152(9):1072. doi:10.1001/jamadermatol.2016.2367. 5) CDC. Clinical Overview of Molluscum Contagiosum. Jan 2025

![](img009_v1.jpg)

8 **Zelsuvmi Has the Potential to Shift MC Treatment Paradigm Zelsuvmi Current Options Painful, destructive** treatments3 **Attractive safety profile** demonstrated in clinical trials with no / minimal scarring5,6 Remaining treatment options such as off-label drugs / natural remedies have **unproven** efficacy4 **Demonstrated, proven efficacy** across key primary and secondary endpoints in clinical trials6 Necessitates travel to HCP offices, adding to the **time burden for MC patients and caregivers**2 **First FDA approved medication** for molluscum that can be applied at home by patients or caregivers5 Other available topical treatment **requires in-office visits every 3 weeks**2 **Daily** application that can be **started immediately 58.1% Mean MC Lesion reduction count(1) *Breakthrough Product, Breakthrough Results*** 1.)Least-squares mean count reduction. See Figure 9: Browning JC, Hebert A, Enloe C, Cartwright M, Maeda-Chubachi T. Berdazimer Gel 10.3% is a Clinically Meaningful Therapeutic Intervention for Molluscum Contagiosum. Abstract and poster presented at Fall Clinical 2024. Las Vegas, NV. October 24-27, 2024. 2.) Eichenf ield LF, Kwong P, Gonzalez ME, et al. Safety and Efficacy of VP-102 (Cantharidin, 0.7% w/v) in Molluscum Contagiosum by Body Region: Post hoc Pooled Analyses from Two Phase III Randomized Trials. J Clin Aesthet Dermatol. 2021;14(10):42-47. 3.) Hebert AA, Bhatia N, Del Rosso JQ. Molluscum Contagiosum: Epidemiology, Considerations, Treatment Options, and Therapeutic Gaps. J Clin Aesthet Dermatol. 2023;16(8 Suppl 1):S4-S11. 4.) Ong SK, Hoft I, Siegfried E. Analysis of over-the-counter products marketed to treat molluscum contagiosum. Pediatr Dermatol. 2021;38(5):1400-1403. doi:10.1111/pde.14776. 5.) Zelsuvmi Package Insert. 6.) Sugarman JL, Hebert A, Browning JC, et al. Berdazimer gel for molluscum contagiosum: An integrated analysis of 3 randomized controlled trials. J Am Acad Dermatol. 2024;90(2):299-308. doi:10.1016/j.jaad.2023.09.066Ong

![](img010_v1.jpg)

9 **Intervention Population Key Study Highlights B-SIMPLE4 Primary Outcome B-SIMPLE4 Study Locations Zelsuvmi Efficacy Shown in Phase 3 Clinical Trials Drives Commercial Launch 808 Males, 790 Females** Immunocompetent children and adults aged ≥6 months with 3-70 raised MC lesions **Mean age: 6.7 years (Range: 0.9 – 76.6 years) 1,598** participants randomized **917 - Zelsuvmi** Topical, once-daily application of Zelsuvmi (berdazimer gel, 10.3%) to all active MC lesions for up to 12 weeks **681 - Vehicle** Topical, once-daily application of vehicle control gel to all active MC lesions for up to 12 weeks Patients who applied Zelsuvmi for 12 weeks achieved a **mean and median reduction in lesion count of 58% and 82%**, respectively, compared to 36% and 43% for patients who applied a vehicle control gel **Mean Lesion Count Reduction(1) 55 Clinics across the US 32.4% of patients** treated with Zelsuvmi achieved complete clearance of MC lesions at week 12, compared to 19.7% of patients treated with vehicle control gel in the BSIMPLE-4 pivotal Phase 3 trial **Median Lesion Count Reduction(1) Safety** Application site reactions were the most common adverse reaction associated with Zelsuvmi Common application site reactions included mild pain and mild erythema (caused by increased blood flow) Minimal scarring incidences witnessed 1) p-value <0.0001, favoring Zelsuvmi .. Source: Sugarman JL, Hebert A, Browning JC, Paller AS, Stripling S, Green LJ, Cartwright M, Enloe C, Wells N, Maeda-Chubachi T. Berdazimer gel for molluscum contagiosum: An integrated analysis of 3 randomized controlled trials. J Am Acad Dermatol. 2023 Oct 5:S0190-9622(23)02890-6. doi: 10.1016/j.jaad.2023.09.066.Epub ahead of print. PMID: 37804936. **58.1% 35.7% Zelsuvmi Control 82.4% 42.6% Zelsuvmi Control**

![](img011_v1.jpg)

10 CONFIDENTIAL **Baseline Week 2 Week 4 0.0% -1.1 % -43.5% Week 8 -35.7% Week 12 -59.4% -82.4% -42.6% -10.7% - 25 .1% -9.0% -21 .6% - 58 .1% Baseline Week 2 Week 4 0.0% 0.0% -9.5% -10.0% -28.6% -27.8% Week 8 Week 12 Phase 3 Trial Results** 1) Figure 9: Browning JC, Hebert A, Enloe C, Cartwright M, Maeda-Chubachi T. Berdazimer Gel 10.3% is a Clinically Meaningful Therapeutic Intervention for Molluscum Contagiosum. Abstract and poster presentedatFall Clinical 2024. Las Vegas, NV. October 24-27, 2024. 2) Figure 10: Browning JC, Hebert A, Enloe C, Cartwright M, Maeda-Chubachi T. Berdazimer Gel 10.3% is a Clinically Meaningful TherapeuticIntervention for Molluscum Contagiosum. Abstract and poster presented at Fall Clinical 2024. Las Vegas, NV. October 24-27, 2024. **Least Squares Mean Lesion Reduction(1) P<0.0001 at all time points, favoring Zelsuvmi Median Lesion Reduction TM (2) Zelsuvmi (n= 917) Vehicle (n= 681)** Zelsuvmi showed statistically significant benefit vs. vehicle after 2 weeks of therapy and through out the entire 12-week length of the Phase 3 studies **Zelsuvmi (n= 917) Vehicle (n= 681)**

![](img012_v1.jpg)

 **Zelsuvmi Commercial Overview**

![](img013_v1.jpg)

12 **Activating Key Leverage Points Is Essential to Maximize the Commercial Potential of Zelsuvmi Addressable Patient Population Refills Treated Patients / Initial Prescriptions Price and Revenue 01 02 03 04 Key Leverage Points Up to 6 million new cases each year with an average untreated resolution time of 13 months, during which disease is highly contagious Treated patients respond well to Zelsuvmi and experience dramatic reduction in lesion count and mean time to resolution FDA approved for 12-week treatment regimen, but internal forecasts assume lower WAC of $1,950 per unit. Disclosed peak net revenues of $175M per annum by 2028**

![](img014_v1.jpg)

13 **Commercial Launch Overview** Fully built out commercial team: Territory managers supported by Sales Training, Marketing, Commercial Operations & Market Access teams Sales Force of 50 Territory Managers Reaching Highest Molluscum Treaters

![](img015_v1.jpg)

14 **Zelsuvmi Tactical Launch ApproachDriving Awareness and Adoption Health Care Providers Education Consumer/Patient Education & Awareness National & Regional Conference Presence Live & Virtual Educational Speaker Development KOL Education Now Available Congress Booth & Virtual Booth MD ZELSUVMI Experience Videos CRM Platform: Education & Communication Telehealth ZELSUVMI GO Patient Support Program How to Start & Use Infographic Brochure Now Available Website with Patient-Specific Education Patient CRM Platform Social Media Banner Ads, Native & Paid Search Patient Testimonial Videos Advocacy & Partnerships**![](img016_v1.jpg)

15 **Strong Uptake of Zelsuvmi in early Launch Phase Zelsuvmi TRx Units Zelsuvmi TRx & HCP Prescribers Week Ending TRx Count TRx Units Prescribers** 7/11/2025 7 7 5 7/18/2025 53 56 37 7/25/2025 89 92 67 8/1/2025 109 109 71 8/8/2025 176 179 126 8/15/2025 199 205 150 8/22/2025 234 244 162 Total 867 892 \*501 **\* Total Unique Prescribers** Data Source: Symphony Health- Metys Data

![](img017_v1.jpg)

**NitricilTM Platform & NaV1.7 Pipeline Overview**![](img018_v1.jpg)

17 **The NitricilTM Platform *Macromolecular platform to achieve stable, tunable and druggable delivery of nitric oxide* Proprietary platform enabling development of NCEs with sustained delivery of nitric oxide Multiple drug candidates with unique nitric oxide delivery and proven target engagement Proprietary formulations, targeted to each indication, enable tunable dosing Tunable Druggable Stable New Chemical Entity (NCE)** Initial Burst Extended Tail **Real-Time Nitric Oxide Release**![](img019_v1.jpg)

18 **Nitricil Platform Pipeline**Asset Description Asset Description Approx Time to NDA Filing Market Potential SB204 (Acne) Berdazimer topical gel, 3.4% for treatment of acne vulgaris. Phase 3 Clinical stage. 4.5 years $$$ SB414 (AD/Psoriasis) Berdazimer topical cream, dose TBD, for treatment of mild to moderate atopic dermatitis. Phase 1/2 Clinical stage. 7.5 years $$$(AD) $$(Psoriasis) SB208 (Tinea Pedis -> Onychomycosis) Low alcohol berdazimer topical gel for treatment of athlete's foot with label expansion for onychomycosis following initial approval. Phase 2/3 Clinical stage. 5 years (T. Pedis) 6.5 years (Onychomycosis) $$$$$ SB208 (Tinea Pedis + Onychomycosis) Low alcohol berdazimer topical gel for treatment of both athlete's foot and onychomycosis. Phase 2/3 Clinical stage. 6.5 years $$$$$ SB207 (EGW/PAW) Berdazimer topical gel, 10.3% for treatment of external genital and perianal warts. Same active gel (Tube A) as Zelsuvmi but different hydrogel (Tube B) formulation. Phase 3 clinical stage. 6.5 years $

![](img020_v1.jpg)

19 **NaV1.7 Pipeline**Product/ Indication Asset Description Approximate Time to NDA Filing Market Potential **CT2000 Eye Drops** Chronic Ocular Pain CC8464 1%, 1.25% and 1.5% ophthalmic solution Phase 1-2a ready 3-4 years $8 billion globally **CT2000 Eye Drops** Acute Ocular Pain CC8464 1%, 1.25% and 1.5% ophthalmic solution Phase 1-2a ready 2-3 years $400 million globally **CT3000 depot** Nerve Blocks CC8464 5% and 10% depot injectable Preclinical Stage 5+ years $300-570 million globally **CC8464 Oral** Erythromelalgia CC8464 melt-granulation capsules 50mg, 100mg, 400mg Phase 1 stage 5+ years $2.4 billion globally **CC8464 Oral** Small Fibre Neuropathy CC8464 melt-granulation capsules 50mg, 100mg, 400mg Preclinical stage 5+ years $50 million – 100 million **CC8464 Oral** Acute Pain CC8464 melt-granulation capsules 50mg, 100mg, 400mg Preclinical stage 5+ years $20 billion globally

![](img021_v1.jpg)

20 CONFIDENTIAL **Key Highlights Strong, Proven Clinical Efficacy In the combined results from the three Phase 3 clinical trials, patients who applied Zelsuvmi for 12 weeks achieved a mean and median reduction in lesion count of 58% and 82%, respectively, compared to 36% and 43% for patients who applied a vehicle control gel Commercially Launched Zelsuvmi was FDA approved In January 2024, and commercially launched in July 2025 as the first and only at-home treatment aimed to revolutionize how MC is treated today for patients ≥ 1 year old Zelsuvmi Differentiated Characteristics Zelsuvmi is a topical gel that uses proprietary nitric oxide release technology and is applied once daily at-home with very good safety profile; opportunity to replace and complement current approved treatment options that are painful and require in-person visits Significant Unmet Need and Sizeable Market Opportunity Large market potential, with up to 6M new cases annually. Treatment of new cases alone has a total addressable market potential of over $20 billion Barriers to Entry Pelthos' bespoke manufacturing processes require a dedicated line and manufacturing of API under extremely high pressures with stringent safety protocols and procedures; robust set of FDA Orange Book listed patents Financial Opportunity Retained Channel Therapeutics' pipeline of several NaV1.7 programs following business combination, providing further upside optionality. Currently exploring best monetization strategies. Biopharmaceutical Platform Poised for Growth Pelthos is strategically positioned to execute and integrate complex, synergistic acquisitions, serving as a platform for investors seeking a strong foothold in the specialty biopharmaceutical market**![](img022_v1.jpg)

21 **Thank You ContactsInvestor Inquiries:**Mike MoyerLifeSci Advisors, LLCManaging Directormmoyer@lifesciadvisors.com**Media:**KWM CommunicationsKellie Walsh / Rachel Kesslerpelthos@kwmcommunications.com(914) 315-6072

## Exhibit 99.2

**Exhibit 99.2**

![](img001_v1.jpg)

**Pelthos Therapeutics to Participate in the 2025 Wells Fargo Healthcare Conference**

*Management's presentation will take place on Wednesday, September 3<sup>rd</sup>, 2025 at 1:30 pm (ET)* 

DURHAM, N.C., Sept. 2, 2025 (GLOBE NEWSWIRE) — Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company ("Pelthos" or the "Company") committed to commercializing innovative therapeutic products for high unmet patient needs, today announced that Scott Plesha, CEO, and Frank Knuettel, CFO, will participate in the Wells Fargo Healthcare Conference. Management's presentation will take place on Wednesday, September 3<sup>rd</sup>, 2025 at 1:30 p.m. E.T.

For one-on-one meeting requests please contact your institutional sales representative. A webcast of the presentation will be available on the Events and Presentations pages of Pelthos' website at <u>https://pelthos.com</u>. Archived replays will be available for 90 days following the event.

**About Pelthos Therapeutics** 

Pelthos Therapeutics is a biopharmaceutical company committed to commercializing innovative, safe, and efficacious therapeutic products to help patients with unmet treatment burdens. The company's lead product ZELSUVMI™ (berdazimer) topical gel, 10.3%, for the treatment of *molluscum contagiosum*, was approved by the U.S. Food and Drug Administration in 2024. More information is available at <u>www.pelthos.com</u>. Follow Pelthos on <u>LinkedIn</u> and <u>X</u>.

**Contacts**

**Pelthos Investor Inquiries:** 

Mike Moyer

Managing Director, LifeSci Advisors, LLC

<u>mmoyer@lifesciadvisors.com</u>

**Media:**

KWM Communications

Kellie Walsh / Rachel Kessler

<u>pelthos@kwmcommunications.com</u>

(914) 315-6072